AN2 Therapeutics, Inc. (ANTX) Stock Forecast
ANTX analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 2 analysts
- Price target
- $9.00 average of analyst targets
- Upside to target
- +166.3% from the latest close
- Next earnings
- November 11, 2026
- 52-week range
- $1.03 – $6.28
ANTX analyst ratings
2 analystsNumber of analysts at each rating.
ANTX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ANTX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.20 | −$0.20 | −$0.20 | −$0.31 | +35.5% | 2 |
| Current fiscal year (2026) | −$0.90 | −$0.93 | −$0.86 | −$1.16 | +22.8% | 2 |
| Next fiscal year (2027) | −$0.80 | −$0.86 | −$0.74 | −$0.90 | +10.6% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ANTX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 2 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 2 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 2 |
ANTX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ANTX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.24 | −$0.24 | −$0.24 | −$0.26 | −$0.20 | −16.7% | 1 up · 0 down |
| Current fiscal year (2026) | −$0.96 | −$0.96 | −$0.96 | −$1.04 | −$0.90 | −6.8% | 1 up · 0 down |
| Next fiscal year (2027) | −$1.04 | −$1.04 | −$1.04 | −$0.93 | −$0.80 | −23.1% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ANTX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ANTX beat in 7 of 12.
What analysts expect from ANTX
2 analysts cover AN2 Therapeutics; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $9.00, 166.3% above the latest close of $3.38. Analysts expect earnings of −$0.90 per share for 2026, +22.8% from a year earlier. For 2027 the average estimate is −$0.80 per share. AN2 Therapeutics beat the EPS estimate in 7 of the last 12 quarters.
Related: ANTX income statement, ANTX key metrics, ANTX chart. See the ANTX stock overview for the latest quote and news.
ANTX forecast FAQ
What is AN2 Therapeutics's price target?
The average analyst price target for AN2 Therapeutics is $9.00, 166.3% above the latest close of $3.38.
Is AN2 Therapeutics a buy, hold or sell?
Of 2 analysts covering AN2 Therapeutics, 2 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is AN2 Therapeutics's EPS forecast?
Analysts forecast −$0.90 per share for 2026 (range −$0.93 to −$0.86); for 2027 the estimate is −$0.80.
When does AN2 Therapeutics report earnings?
AN2 Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.
Does AN2 Therapeutics usually beat earnings estimates?
AN2 Therapeutics reported EPS at or above the analyst estimate in 7 of the last 12 quarters.